Halozyme offers $1.05B convertible notes due 2033
Halozyme Therapeutics announced a proposed offering of $1.05 billion of convertible senior notes due 2033, subject to market conditions. This offering is relevant as it provides additional liquidity and potential capital structure adjustments.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed